An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
LivaNova PLC issued a notice to U.S. patients about a cybersecurity incident, exposing personal information. The incident, discovered on November 19, 2023, involved unauthorized access to patient data. The compromised information includes personal details, medical records, and health insurance data. LivaNova took immediate action to address the issue and is offering identity protection services to affected patients.
LivaNova PLC ha emesso un avviso ai pazienti statunitensi riguardo un incidente di sicurezza informatica che ha esposto informazioni personali. L'incidente, scoperto il 19 novembre 2023, ha coinvolto l'accesso non autorizzato ai dati dei pazienti. Le informazioni compromesse includono dettagli personali, registri medici e dati relativi alle assicurazioni sanitarie. LivaNova ha agito immediatamente per risolvere il problema e sta offrendo servizi di protezione dell'identità ai pazienti colpiti.
LivaNova PLC emitió un aviso a los pacientes de EE. UU. sobre un incidente de ciberseguridad que expuso información personal. El incidente, descubierto el 19 de noviembre de 2023, involucró el acceso no autorizado a los datos de los pacientes. La información comprometida incluye detalles personales, registros médicos y datos de seguros de salud. LivaNova tomó medidas inmediatas para abordar el problema y está ofreciendo servicios de protección de identidad a los pacientes afectados.
리바노바 PLC는 미국 환자들에게 개인 정보를 노출시키는 사이버 보안 사고에 대해 통지하였습니다. 2023년 11월 19일에 발견된 이 사고는 환자 데이터에 대한 무단 접근을 포함하고 있습니다. 침해된 정보에는 개인적인 세부사항, 의료 기록, 그리고 건강 보험 데이터가 포함됩니다. 리바노바는 즉시 문제를 해결하기 위해 행동을 취했으며, 피해를 입은 환자들에게 신원 보호 서비스를 제공하고 있습니다.
LivaNova PLC a émis un avis aux patients américains concernant un incident de cybersécurité, exposant des informations personnelles. L'incident, découvert le 19 novembre 2023, impliquait un accès non autorisé aux données des patients. Les informations compromises comprennent des détails personnels, des dossiers médicaux et des données d'assurance santé. LivaNova a pris des mesures immédiates pour résoudre le problème et offre des services de protection de l'identité aux patients affectés.
LivaNova PLC hat eine Mitteilung an US-Patienten über einen Vorfall in der Cybersicherheit herausgegeben, der persönliche Informationen preisgab. Der Vorfall, entdeckt am 19. November 2023, beinhaltete unautorisierten Zugriff auf Patientendaten. Die kompromittierten Informationen umfassen persönliche Details, medizinische Unterlagen und Daten der Gesundheitsversicherung. LivaNova ergriff sofort Maßnahmen, um das Problem anzugehen, und bietet den betroffenen Patienten Dienste zum Schutz ihrer Identität an.
Positive
None.
Negative
None.
LONDON--(BUSINESS WIRE)--
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a cybersecurity incident that was initially disclosed by the Company on November 20, 2023.
The incident resulted in a disruption to portions of the Company’s information technology systems. Promptly after detecting the issue on November 19, 2023, LivaNova began an investigation with assistance from external cybersecurity experts and coordinated with law enforcement. The Company took action to remediate the issue, such as taking certain systems offline, and resumed manufacturing as previously disclosed. In the course of its investigation, the Company determined that its systems were first accessed by an unauthorized party around October 26, 2023.
On April 10, 2024, LivaNova learned that the unauthorized party obtained certain identifiable personal information of U.S. patients. While the Company is continuing to analyze the nature and scope of the affected information, the Company is aware that the information, which varied by impacted individual, included data such as name, contact information (e.g., phone number, email and postal address), Social Security number, date of birth, medical information (e.g., treatment, condition, diagnosis, prescription, physician, medical record number and device serial number), and health insurance information.
On April 25, 2024, LivaNova posted notice of this incident on its website. The Company is sending notice to affected U.S. patients for whom it has contact information. The Company’s notice of this incident includes information on how affected U.S. patients can enroll in complimentary identity protection and credit monitoring services. LivaNova encourages affected patients in the U.S. to remain vigilant for incidents of fraud and identity theft by reviewing their account statements and monitoring their free credit reports, and to remain alert for unsolicited communications involving personal information.
Affected U.S. patients who have questions or would like additional information about this issue can contact (833) 931-5100 toll-free, Monday through Friday, 8 a.m. to 8 p.m. CT (excluding major U.S. holidays). Please reference engagement number B121304 when calling. Additional information is available atwww.livanova.com.
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the Company’s previously disclosed cybersecurity incident. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
What did LivaNova announce to U.S. patients regarding a cybersecurity incident?
LivaNova issued a notice to U.S. patients about a cybersecurity incident involving unauthorized access to patient data.
When was the cybersecurity incident first detected by LivaNova?
The cybersecurity incident was first detected by LivaNova on November 19, 2023.
What type of personal information was compromised in the cybersecurity incident?
The compromised personal information included name, contact details, Social Security number, medical records, and health insurance information.
What actions did LivaNova take after detecting the cybersecurity incident?
LivaNova took immediate action by working with cybersecurity experts, taking certain systems offline, and offering identity protection services to affected patients.
How can affected U.S. patients enroll in complimentary identity protection and credit monitoring services?
Affected U.S. patients can enroll in complimentary identity protection and credit monitoring services by following the instructions provided in the notice from LivaNova.
livanova plc is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.at livanova, we understand the importance of bringing both clinical and economic value to our customers. we are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. livanova is listed on the nasdaq stock exchange under the ticker symbol “livn.” livanova has approximately 3,000 employees worldwide. we are headquartered in london (uk) and maintain a presence in more than 100 countries. livanova is a worldwide leader in advanced circulatory support, cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.
